Your cholesterol numbers came back normal. Your LDL is in range. Your doctor is satisfied. You leave the appointment believing your heart is well-protected.
For roughly one in five people worldwide, that belief may be dangerously incomplete.
A growing body of research, a landmark new NIH-backed analysis of more than 20,000 patients, and sweeping new national guidelines released in March 2026 are all pointing to the same urgent conclusion: there is a cholesterol risk hiding in the bloodstream of approximately 20% of the global population that standard lipid panels simply do not measure. It is called lipoprotein(a), abbreviated as Lp(a), and until recently, most patients had never heard of it, and most doctors had never ordered a test for it.
That is beginning to change. But not fast enough.
What Lp(a) Is and Why It Is Different
Lp(a) is a cholesterol-carrying particle that circulates in the bloodstream much like LDL cholesterol. It resembles LDL in structure, but carries an additional protein called apolipoprotein(a) that is thought to make it significantly more harmful to the cardiovascular system. Where LDL contributes to atherosclerosis by depositing cholesterol into arterial walls, Lp(a) appears to promote inflammation, arterial stiffness, and blood clot formation as well.
The critical distinction between Lp(a) and other cholesterol markers is their origin. LDL levels are heavily influenced by diet, exercise, and medication, the lifestyle factors that conventional heart disease prevention is built around. Lp(a) levels, by contrast, are more than 90% genetically determined. They are set at birth, remain largely stable throughout life, and respond only minimally to statins, dietary changes, or the other standard interventions cardiologists routinely recommend.
This means that a person with high Lp(a) can follow every piece of standard cardiovascular advice to the letter, take their statin, watch their saturated fat intake, exercise regularly, and still carry a significantly elevated risk of heart attack and stroke that none of those interventions meaningfully addresses. The risk is real. The standard toolkit largely does not touch it.
The Scale of the Problem
The numbers involved are not small. Elevated Lp(a), defined as levels above 125 nanomoles per liter or 50 milligrams per deciliter, affects roughly one in five people worldwide. In absolute terms, that translates to more than a billion people globally carrying a cardiovascular cholesterol risk that is not captured by the blood test their doctor almost certainly ordered.
A major new analysis presented at the Society for Cardiovascular Angiography and Interventions 2026 Scientific Sessions in Montreal examined data from more than 20,000 patients across three large NIH-funded studies. The full findings are documented through the Society for Cardiovascular Angiography and Interventions 2026 research presentations and confirm that elevated Lp(a) is tied to ongoing cardiovascular cholesterol risk even in people who are already receiving standard cholesterol-lowering treatment. Patients with high Lp(a) levels, the analysis found, may need substantially more aggressive management of other heart disease risk factors to compensate for a risk their current medication does not address.
The testing gap compounds the problem. Despite affecting one in five people globally, Lp(a) testing rates remain remarkably low. According to data cited in the new 2026 guidelines from the American College of Cardiology and the American Heart Association, less than 5% of Americans have ever had their Lp(a) measured. In the INTERHEART study from the Middle East and Gulf region, which enrolled nearly 600,000 subjects, only one in fifty patients had been tested for Lp(a) even among those under active cardiovascular care.
New Guidelines Finally Address the Gap
The March 2026 update to US dyslipidemia guidelines, the first comprehensive revision in eight years, represents a significant turning point in how Lp(a) is officially recognized within clinical practice.
The new ACC/AHA guidelines now recommend that all adults have their Lp(a) measured at least once as part of a cardiovascular risk assessment. They also introduce universal lipid screening for children between ages 9 and 11, set more aggressive LDL targets based on individual risk categories, and formally include women’s reproductive history in standard cardiovascular risk assessment for the first time.
For the Lp(a) question specifically, the guidelines now classify elevated Lp(a) as a formal risk-enhancing factor. Values above 125 nanomoles per liter are associated with approximately a 1.4-fold increased risk of atherosclerotic cardiovascular disease. Values above 250 nanomoles per liter carry even greater risk. These figures come from the full ACC/AHA guideline on the management of dyslipidemia published in the journal Circulation, representing the most authoritative current statement on cardiovascular risk management in the United States.
The Family Heart Foundation, which tracks inherited cholesterol disorders, described the guideline update as “a significant milestone,” noting that it reflects growing recognition of inherited cholesterol risks that have long been underdiagnosed but can dramatically increase the risk of heart attack, stroke, and other cardiovascular events.
This shift connects to a broader transformation in how medicine is rethinking cholesterol management, moving from a single-number approach toward a more complete picture of cardiovascular risk that accounts for genetic factors standard tests have historically overlooked, a theme explored in how researchers are finding new ways to identify and address cholesterol risks that conventional medicine has missed.
Why Your Standard Cholesterol Panel Misses It
The standard lipid panel ordered during routine checkups measures four things: total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. It does not measure Lp(a). It does not measure ApoB, another marker that the new guidelines are now recommending. And it does not capture the full picture of cardiovascular cholesterol risk for a significant minority of patients.
The reason Lp(a) was excluded from standard panels for so long is partly historical and partly practical. When lipid testing protocols were developed and standardized decades ago, the evidence base for Lp(a) as an independent risk factor was not yet as strong as it is today. Testing technology was also less accessible. And because Lp(a) levels are genetically fixed and largely unresponsive to available treatments, there was a clinical argument that testing for something you could not treat was of limited value.
That argument has weakened significantly in recent years. Even without Lp(a)-specific treatments, knowing your Lp(a) level changes clinical management in important ways. It can trigger more aggressive treatment of modifiable risk factors like LDL, blood pressure, and blood sugar. It can inform decisions about preventive medications. It can prompt earlier and more frequent cardiovascular screening. And it can lead to cascade testing of family members, since high Lp(a) is inherited, and a single positive result in one person has implications for their biological relatives.
The calcified coronary artery score, a measure of plaque buildup in the arteries, has also emerged in the new guidelines as a tool for refining risk assessment in patients whose Lp(a) levels place them in an uncertain category. Together, these tools are beginning to build a more complete picture of cardiovascular cholesterol risk than the four-number panel that has dominated clinical practice for decades.
The Treatment Horizon
The most significant remaining gap in the Lp(a) story is therapeutic. Currently, no approved medication specifically targets Lp(a) reduction with proven cardiovascular benefit. Statins, which are highly effective at lowering LDL, reduce Lp(a) by only about 10% to 15% on average, and some research suggests they may even slightly increase Lp(a) in certain patients. PCSK9 inhibitors, which represent a newer generation of cholesterol-lowering drugs, reduce Lp(a) modestly but not enough to specifically address high-risk levels.
That is changing. Several RNA-based therapies specifically designed to lower Lp(a) are currently in late-stage clinical trials. Olpasiran, a small interfering RNA therapy, reduced Lp(a) by more than 90% in phase 2 trials. Lepodisiran, another siRNA approach, showed similarly dramatic reductions in a phase 2 trial published in JAMA in 2025. Zerlasiran is in its own phase 2 trial, the ALPACAR-360 study.
The critical question of whether reducing Lp(a) with these drugs actually reduces cardiovascular events is being tested in large phase 3 outcomes trials expected to report results within the next two to three years. If those trials confirm benefit, the landscape of cardiovascular medicine will shift considerably. A condition affecting one billion people, previously untreatable with any targeted approach, would have a specific therapy for the first time.
Muvalaplin, an oral drug targeting Lp(a), also showed significant reductions in the KRAKEN trial published in JAMA in 2025, raising the possibility of a pill-based approach that could reach patients in lower-income countries where injectable biologics are difficult to access. This accessibility dimension connects directly to broader questions about how cardiovascular medicine addresses the gap between what science can measure and what patients in lower-resource settings can afford to treat, a theme explored in how healthcare access shapes who benefits from medical breakthroughs.
What You Can Do Right Now
The most actionable takeaway from the 2026 guidelines and the broader Lp(a) evidence base is simple: ask your doctor for an Lp(a) test.
The test is a standard blood draw. It is not expensive. It needs to be done only once in most cases, since Lp(a) levels remain relatively stable throughout life. And for the roughly one in five people who will discover they have elevated levels, the result can meaningfully change how their cholesterol risk is managed.
For people with a family history of early heart disease, the case for testing is even stronger. Because Lp(a) is genetically determined, a family pattern of premature cardiovascular events should prompt Lp(a) testing regardless of whether standard cholesterol numbers look normal. The Family Heart Foundation offers free home screening kits through its Cholesterol Connect program for those who want to test outside of a clinical setting, and their resources for navigating results with a care advisor are available to the public. Full details on accessing Lp(a) testing and interpreting results are available through the Family Heart Foundation’s cardiovascular screening program.
The new 2026 guidelines represent a long-overdue correction to a gap in standard cardiovascular care. But guidelines move faster than clinical practice, and there will be a lag of months or years before Lp(a) testing becomes routine in every primary care office. In the meantime, patients who are aware of the issue can drive it themselves.
Looking Ahead
The Lp(a) story is, at its core, a story about the limits of what standard medicine measures and the consequences of those limits for patients who fall outside the frame. For decades, cardiovascular risk assessment was built around LDL cholesterol because it was measurable, modifiable, and strongly predictive. That framework served millions of people well. But it left one in five in a blind spot.
The convergence of better evidence, updated guidelines, and a pipeline of promising targeted therapies is finally closing that gap. The question of whether Lp(a) reduction translates into cardiovascular benefit is the most important unanswered question in preventive cardiology right now, and the answer is coming within this decade.
For the patients carrying a hidden cholesterol risk without knowing it, that answer cannot come soon enough. Understanding the full picture of cardiovascular risk, not just the numbers a standard panel provides, may be one of the most consequential things a person can do for their long-term health. The tools to see that picture clearly are, at last, beginning to arrive.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions about cholesterol testing or treatment.
